<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238822</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH074770</org_study_id>
    <nct_id>NCT01238822</nct_id>
  </id_info>
  <brief_title>Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>Response Variability in Children With ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children with Attention Deficit Hyperactivity Disorder (ADHD) have numerous areas of
      neuropsychological dysfunction including response inhibition, working memory, and attention.
      One neuropsychological outcome measure that consistently reveals between-group differences is
      response variability. However, until recently, differences in response variability have been
      reported as an ancillary finding or viewed as a nuisance in the analyses. The specific aims
      of the present study are to 1) Examine response variability in ADHD patients across
      neuropsychological tasks to understand the breadth of this specific deficit and to understand
      the relation between response variability and other neuropsychological outcome measures; 2)
      Assess whether response variability deficits are specific to either or both of the two most
      prevalent ADHD subtypes (i.e., Combined Type [CT] and Predominantly Inattentive Type [PIT]);
      3) Determine whether response variability in ADHD patients is affected by either medication
      or a variety of environmental manipulations (e.g., reward); and 4) Understand the
      relationship between neuropsychological measures of response variability and naturalistic
      instances of variable performance. Forty-five children (aged 7-11) with ADHD-CT, 45 children
      with ADHD-PIT, and 45 normal controls will be recruited to examine response variability
      across a wide range of neuropsychological tests. Task parameters such as event rate, stimulus
      saliency, and the presence of operant reward will be modified on each test to determine the
      conditions under which response variability is manifested in children with ADHD. In addition,
      all children with ADHD will participate in a placebo-controlled, randomized medication trial
      with a psychostimulant medication to assess the effects of medication on response
      variability. Advanced analytic methods utilizing non-Gaussian distributions and fast Fourier
      Transforms of the reaction time data will be used to conduct detailed analyses of RT patterns
      across the ADHD and normal control groups. Further, the effects of task parametric
      manipulations and medication on response variability will be examined. Finally, relations
      between response variability on neuropsychological tests and response variability in a
      variety of real-world analog situations will be examined to evaluate the ecological validity
      of these deficits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Attention Deficit / Hyperactivity Disorder Total Sum Score of All 18 ADHD Symptom Items</measure>
    <time_frame>end of first week, end of second week, end of third week, end of fourth week. Total of 4 weeks.</time_frame>
    <description>Parent and teacher Vanderbilt ADHD Rating Scales - Attention Deficit / Hyperactivity Disorder Total sum score of all 18 ADHD symptom items - range equals 0-54
O - No ADHD symptoms 54 - Highest ADHD symptoms</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Methylphenidate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose: 18 mg methylphenidate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose Methylphenidate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medium Dosage: 36 mg if more than 50 kg and 27 mg if less than 50 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Methylphenidate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>54 mg if more than 50 kg and 36 mg if less than 50 kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>18 mg methylphenidate</description>
    <arm_group_label>Low Dose Methylphenidate</arm_group_label>
    <other_name>Concerta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>36 mg methylphenidate</description>
    <arm_group_label>Medium Dose Methylphenidate</arm_group_label>
    <other_name>Concerta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>54 mg methylphenidate</description>
    <arm_group_label>High Dose Methylphenidate</arm_group_label>
    <other_name>Concerta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria. Participants for the study must meet all of the following criteria:

          1. Consent: The family must provide signature of informed consent by parents or legal
             guardians.

          2. Age at time of Screening: 7 years to 11 years, inclusive

          3. Gender: includes male and female children.

          4. ADHD Diagnostic Status: ADHD patients must meet DSM-IV criteria for ADHD, Inattentive
             or Combined subtype. Normal controls must not meet DSM-IV criteria for ADHD, any
             subtype. Section D.4 below describes in detail the diagnostic process for arriving at
             diagnosis.

          5. Cognitive Functioning: IQ of greater than 80 as estimated by Vocabulary and Block
             Design subtests of the Wechsler Intelligence Scale for Children, Fourth Edition
             (WISC-IV).

          6. Learning Disability: All children will be administered the abbreviated WIAT including
             the Spelling, Reading, and Math subtests. Children must score above 80 on all three
             WIAT subtests.

          7. School: Children must be enrolled in a school setting from which teacher ratings can
             be obtained.

        Exclusion Criteria. Potential participants will be excluded if they meet any of the
        following criteria:

          1. Understanding Level. The patient and parent cannot understand or follow instructions
             given in the study.

          2. History of Psychiatric Medications: Children who have a history of taking any
             medication for psychological or psychiatric problems will be excluded from
             participation.

          3. Exclusionary Psychiatric Conditions: Children whose primary diagnosis is something
             other than ADHD will be excluded from participation.

          4. Developmental Disabilities. As a result of scores on the IQ screening, additional
             assessments, or the judgment of the study clinicians, patients will be excluded if
             they are deemed to be significantly developmentally delayed. This includes clinically
             significant delays in cognitive function or the presence of other Pervasive
             Developmental Disorders (PDD).

          5. Organic Brain Injury: Children must not have a history of head trauma, neurological
             disorder, or any other organic disorder that could possibly affect brain function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <results_first_submitted>July 14, 2011</results_first_submitted>
  <results_first_submitted_qc>April 2, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2012</results_first_posted>
  <last_update_submitted>April 2, 2012</last_update_submitted>
  <last_update_submitted_qc>April 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Children were recruited through multiple community and clinical sources including schools and local practitioners to participate in a study of the effects of medication on cognitive functioning. Diagnostic status was determined using methodology similar to that employed by the Multimodal Treatment Study of ADHD (MTA Cooperative Group, 1999).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>All participants received 3 weekly doses of methylphenidate at a low dose (18 mg), medium dosage (27 mg or 36 mg depending on weight) and a high dosage (52 mg or 36 mg depending on weight) and another week of placebo. Patients took each dosage for 1 week and parents and teachers rated their behavior at the end of each week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Placebo</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Low Dosage</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Medium Dosage</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received High Dosage</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>COULD NOT SWALLOW PILLS</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants received 3 weekly doses of methylphenidate at a low dose (18 mg), medium dosage (27 mg or 36 mg depending on weight) and a high dosage (52 mg or 36 mg depending on weight) and another week of placebo. Patients took each dosage for 1 week and parents and teachers rated their behavior at the end of each week.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.11" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Attention Deficit / Hyperactivity Disorder Total Sum Score of All 18 ADHD Symptom Items</title>
        <description>Parent and teacher Vanderbilt ADHD Rating Scales - Attention Deficit / Hyperactivity Disorder Total sum score of all 18 ADHD symptom items - range equals 0-54
O - No ADHD symptoms 54 - Highest ADHD symptoms</description>
        <time_frame>end of first week, end of second week, end of third week, end of fourth week. Total of 4 weeks.</time_frame>
        <population>Intent to treat with imputation for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
          <group group_id="O2">
            <title>Low Dosage</title>
            <description>18 mg methylphenidate</description>
          </group>
          <group group_id="O3">
            <title>Medium Dosage</title>
            <description>36 mg methylphenidate if &gt;25 kg; 27 mg methylphenidate if &lt; 25 kg.</description>
          </group>
          <group group_id="O4">
            <title>High Dosage</title>
            <description>54 mg methylphenidate if &gt;25 kg; 36 mg methylphenidate if &lt; 25 kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Attention Deficit / Hyperactivity Disorder Total Sum Score of All 18 ADHD Symptom Items</title>
          <description>Parent and teacher Vanderbilt ADHD Rating Scales - Attention Deficit / Hyperactivity Disorder Total sum score of all 18 ADHD symptom items - range equals 0-54
O - No ADHD symptoms 54 - Highest ADHD symptoms</description>
          <population>Intent to treat with imputation for missing data.</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.54" spread="12.03"/>
                    <measurement group_id="O2" value="25" spread="12.73"/>
                    <measurement group_id="O3" value="18.94" spread="11.18"/>
                    <measurement group_id="O4" value="18.46" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Low Dosage</title>
          <description>Low dose: 18 mg methylphenidate</description>
        </group>
        <group group_id="E3">
          <title>Medium Dosage</title>
          <description>Medium Dosage: 36 mg methylphenidate</description>
        </group>
        <group group_id="E4">
          <title>High Dosage</title>
          <description>54 mg methylphenidate</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Parent-reported crabby, irritable</sub_title>
                <description>Number rated 4 (severe)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Parent-reported loss of appetite</sub_title>
                <description>Number rated 4 (severe)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Parent-reported buccal-lingual movements</sub_title>
                <description>Number rated 4 (severe)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Parent-reported picking at skin or fingers, nail-biting, or cheek chewing</sub_title>
                <description>Number rated 4 (severe)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Parent-reported dull, tired, listless</sub_title>
                <description>Number rated 4 (severe)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Parent-reported headaches</sub_title>
                <description>Number rated 4 (severe)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Parent-reported stomachache</sub_title>
                <description>Number rated 4 (severe)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Parent reported tics</sub_title>
                <description>Number rated 4 (severe)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Parent-reported worried/anxious</sub_title>
                <description>Number rated 4 (severe)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Parent-reported tearful, sad, depressed</sub_title>
                <description>Number rated 4 (severe)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Parent-reported socially withdrawn</sub_title>
                <description>Number rated 4 (severe)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Parent-reported hallucinations</sub_title>
                <description>Number rated 4 (severe)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Parent-reported trouble sleeping</sub_title>
                <description>Number rated 4 (severe)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeff Epstein</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <email>jeff.epstein@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

